Glover A B, Leyland-Jones B R, Chun H G, Davies B, Hoth D F
Cancer Treat Rep. 1987 Jul-Aug;71(7-8):737-46.
Azacitidine has been undergoing clinical trials for almost 20 years and is internationally considered to have a useful place in the treatment of acute nonlymphocytic leukemia. However, its role in the various combinations for induction, intensification, maintenance, or relapse regimens has not yet been clearly defined. This review outlines the last 10 years' clinical experience with the drug in acute nonlymphocytic leukemia, analyzes what critical information has yet to be obtained, and suggests what phase III trials may still be feasible to gather that information.
阿扎胞苷已经历了近20年的临床试验，在国际上被认为在急性非淋巴细胞白血病的治疗中占有一席之地。然而，其在诱导、强化、维持或复发方案的各种联合应用中的作用尚未明确界定。本综述概述了该药物在急性非淋巴细胞白血病方面过去10年的临床经验，分析了尚未获得的关键信息，并提出了哪些III期试验可能仍可行以收集这些信息。
